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1. Introduction
This chapter provides an overview of the main current applications of gene therapy for chronic
pain in what concerns animal studies and putative clinical applications. The value of gene
therapy in unravelling neuronal brain circuits involved in pain modulation is also analysed.
After alerting to the huge socioeconomic impact of chronic pain in modern societies and
justifying the need to develop new avenues in pain management, we review the most common
animal studies using gene therapy, which consisted on deliveries of replication-defective viral
vectors at the periphery with the aim to block nociceptive transmission at the spinal cord.
Departing from the data of these animal studies, we present the latest results of clinical trials
using gene therapy for pain management in cancer patients. The animal studies dealing with
gene delivery in pain control centres of the brain are analysed in what concerns their com‐
plexity and interest in unravelling the neurobiological mechanisms of descending pain
modulation. The chapter will finish by analysing possible futures of gene therapy for chronic
pain management based on the development of vectors which are safer and more specific for
the different types of chronic pain.
2. Chronic pain: A burden for modern societies
Pain is not easy to define since it is a highly subjective experience. The more consensual
definition of pain was provided by the International Association for the Study of Pain (IASP)
and states that “Pain is an unpleasant sensory and emotional experience associated with actual or
potential tissue damage, or described in terms of such damage” [1]. Acute pain is important as an
alert signal to potentially threaten situations (internal or external to the organism) and it is
important for survival. Acute pain may progress to chronic pain which, according to IASP, is
the pain that lasts more than 3 months and persists beyond the normal tissue healing time [2].
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Chronic pain may be divided into "nociceptive" and "neuropathic" [3]. Nociceptive pain is
caused by activation of nociceptors, the thin nerve fibers which convey nociceptive input from
the periphery to the spinal cord. Neuropathic pain is caused by malfunction or damage of the
nervous system. Neuropathic pain is frequently difficult to treat being associated to sponta‐
neous pain, exaggerated responses to nociceptive stimuli (hyperalgesia) and nociceptive
responses to stimuli which are usually non-nociceptive (allodynia).
The number of people affected by chronic pain is increasing due to multifactorial causes such
as increasing aging of the population. In Europe, about 20% of people suffer from moderate
to severe chronic pain [4]. In the United States the prevalence of chronic pain ranges from 2%
to 40%, with a median of 15% [5], which cost the country 560 to 635 million dollars [6]. People
suffering from chronic pain are less able to walk, sleep normally, perform social activities,
exercise or have sexual relations. Chronic pain strongly affects the productivity. About 60% of
chronic pain patients are unable or less able to work, 19% lost their jobs and 13% change jobs
due to their pain [6]. Chronic pain is associated to several co-morbidities, namely depression
and anxiety [6]. Besides all of these indirect costs, chronic pain is a burden due to direct costs
of pain management. Despite major investments in basic and clinical pain research, the
available analgesics remain considerably unchanged during the last decades. Opioids are
useful to manage several pain types but they have a modest efficacy in several pain conditions
(e.g. neuropathic pain). Furthermore, long term treatments with opioids frequently induce
severe off-target effects, like nausea, constipation and addiction [7]. Intractable pain remains
a clinical problem and a drama for the patients and their families [8]. During the last decade,
pain clinicians and pain researchers were challenged to search for alternatives to conventional
pain treatment, which should be more specific and sustained than conventional analgesics.
Gene therapy outstands as a powerful technique to overcome some current problems of
chronic pain treatments.
Neurobiological research in the pain field provided solid information regarding the transmis‐
sion and modulation of nociceptive information from the periphery to the brain, where a pain
sensation is produced (Fig. 1). Nociceptive signals are conveyed by primary afferent fibers
from peripheral organs, like the bladder or muscles, to the spinal cord. This is the first relay
station involved in the modulation of nociceptive information namely by local inhibitory
interneurons that use opioid peptides or aminoacids (γ-amminobutiric acid-GABA- and
glycine). Nociceptive information is then transmitted supraspinally, namely to the thalamus,
and to several brainstem areas, where additional modulation of the nociceptive signal occurs.
The thalamo-cortical pathway ensures that the nociceptive information reaches the somato‐
sensory and prefrontal cortices, where the nociceptive signal is finally perceived as a pain
sensation [9, 10]. Some brain areas which directly or indirectly receive nociceptive information
from the spinal cord are also involved in descending pain modulation. Both inhibition and
facilitation may occur and chronic pain may derive from a reduction of the former and
enhancement of the latter [9, 11]. This neurobiological knowledge has been used to design gene
therapy studies for chronic pain, namely to choose the somatosensory system areas and
neurotransmitters/receptors to be targeted in order to block nociceptive transmission.
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Figure 1. Schematic diagram of pain pathways involved in pain transmission and modulation. Nociceptive informa‐
tion is transmitted from the periphery to the spinal dorsal horn by primary sensory neurons. At the spinal level, these
neurons transmit nociceptive information to second order neurons (“Ascending pathways”) through the release of
neurotransmitters like the excitatory amino acids (EAA) glutamate and aspartate, calcitonin gene-related peptide
(CGRP), substance P (SP) galanin (Gal) and neuropeptide Y (NPY). In the brain, the nociceptive information is then per‐
ceived as a pain sensation. The transmission of nociceptive information at the spinal level is modulated by interneur‐
ons (mainly inhibitory) through the release of opioid pepides and GABA and also by supraspinal descending neurons
(“Descending pathways”) through the release of serotonin (5-HT) and noradrenaline (NA). Descending pathways may
inhibit or enhance nociceptive transmission from the spinal cord.
Gene therapy is an especially versatile tool for chronic pain management since it is based in a
triad of controllable parameters: the vector, the transgene and the promoter. By knowing the
neurobiological features of each chronic pain type, namely the neurotransmitters and receptors
affected, it is possible to design gene therapy strategies based on the best combination of
vectors, transgenes and promoters. As to vectors, gene therapy for pain uses mainly “vehicles”
which have a “certified” experience in infecting neurons, namely replication-defective forms
of viruses. Non-viral vectors have seldom been used in gene therapy studies for pain but their
transduction efficiency and specificity are much lower than those of viral vectors. Some of
these vectors have the ability to migrate retrogradely (i.e., contrary to the direction of nerve
impulse) which is very useful to target neurons that are located in structures of difficult surgical
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access. A good example is the application of replication-defective forms of Herpes Simplex
Virus type 1 (HSV-1) at the periphery (e.g. the skin) to transduce neurons at the spinal ganglia
(dorsal root ganglia-DRGs), which are difficult to access due to their bone protection. Regard‐
ing the transgenes to include in the vectors for gene therapy of pain, it is possible to increase
the expression of neurotransmitters and receptors involved in nociceptive inhibition (e.g.
opioids), neurotrophic factors or substances with anti-inflammatory properties. Finally, and
in what concerns the promoters, it is possible to choose those that restrict transgene expression
to a cell type, such as a neuron or a glial cell, or even target selective neurochemical neuronal
populations. Examples of neuron-specific promoters are synapsin I, calcium/calmodulin-
dependent protein kinase II, tubulin alpha I and neuron-specific enolase [12]. Some possibili‐
ties of controlling the vectors, transgenes and promoters will be discussed in the next two
sections using gene therapy in animal models.
3. Gene therapy targeting the spinal cord in animal pain models
One  of  the  main  advantages  of  experimental  gene  therapy  studies  is  that  they  can  be
performed using several pain models. This is important since each pain type may induce
specific  changes  in  neuronal  circuits  devoted  to  the  transmission  and  modulation  of
nociceptive transmission [13]. Studies of gene therapy for pain have used clinically relevant
models of inflammatory [14-22] and neuropathic pain [23-34]. In a much lower incidence,
models of acute [35-38], post-operative pain [39] and cancer [40] pain have been used in
experimental gene therapy studies. The large majority of studies were performed in pain
models affecting the limbs or the trunk, in the latter case being of visceral origin [22, 37].
Two studies used gene therapy to block nociceptive transmission coming from the head/
face  in  pain  models  that  reproduces  some  types  of  craniofacial  pain,  like  trigeminal
neuralgia [41] or temporomandibular joint disorders [42].
Gene therapy studies for pain in animal models may be divided in studies targeting the spinal
cord (Table 1) and studies directed to pain control centres located in the brain (Table 2). Studies
directed to the spinal cord mainly aim to manipulate the expression of transgenes in order to
block the transmission of nociceptive input at the spinal dorsal horn (Table 1). Most of the
spinal cord studies using gene therapy for pain elected HSV-1 as the most suitable vector, due
to its natural affinity to the neuron and its ability for retrograde transport [43]. HSV-1 has the
additional advantage over other vectors of carrying multiple transgenes or large transgenes
and not integrating in the host genome, which reduces the possibility of mutagenic events [44,
45]. After application of replication-defective forms of HSV-1 at the periphery in order to
transduce DRG neurons (or trigeminal ganglion neurons), delivery of the transgene product
by the spinal branch of transduced neurons at the spinal dorsal horn induced analgesia in
several rodent models of pain (Table 1). Gene therapy in animal models of craniofacial pain
[41, 42] aimed to release the transgene products at the level of the spinal trigeminal nucleus
and this structure is homolog of the spinal cord, which prompted to include these studies in
the section devoted to spinal cord studies.
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Pain models Gene product Inoculation References
Herpes Simplex type 1
Acute pain Pre-proenkephalin Subcutaneous [35]
Inflammatory pain Pre-proenkephalin A Subcutaneous [14]
Neuropathic pain Pre-proenkephalin A Subcutaneous [41]
Cutaneous hyperalgesia Pre-preproenkephalin Subcutaneous [36]
Bladder hyperactivity Pre-preproenkephalin Bladder wall [37]
Inflammatory pain Endomorphin-2 Subcutaneous [15]
Neuropathic pain Endomorphin-2 Subcutaneous [23]
Neuropathic pain IL-4 Subcutaneous [24]
Neuropathic pain sTNFRs Subcutaneous [25]
Neuropathic pain GAD Subcutaneous [26, 47]
Chronic pancreatitis Pre-proenkephalin Pancreas surface [22]
Inflammatory pain Nav1.7 antisense Subcutaneous [16]
Incision pain Pre-proenkephalin Subcutaneous [39]
Cancer pain Pre-proenkephalin Subcutaneous [40]
Adenovirus
Inflammatory pain GAD Trigeminal ganglion [42]
Neuropathic pain IL-10 Intrathecal [27]
Inflammatory pain β-endorphin Intrathecal [17]
Neuropathic pain IL-2 Intrathecal [28]
Adeno-associated vectors
Neuropathic pain IL-10 Intrathecal [29]
Neuropathic pain shGCH1 Intrathecal [30]
Neuropathic pain Prepro- β-endorphin Intrathecal [31]
Inflammatory pain µ-opioid receptors DRG [18]
Lentivirus
Neuropathic pain GDNF Intraspinal [32]
Neuropathic pain NFκB Repressor Intraspinal [33]
Table 1. Summary of experimental studies using viral vectors for gene transfer to the spinal cord.
As to the transgenes included in the HSV-1 vectors, opioid peptides or their precursors largely
prevail due to their well-known ability to block nociceptive transmission at the spinal cord.
HSV-1-based delivery of opioids has additional advantages over classic opioids, namely by
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being deprived of major side-effects and preventing tolerance after repeated administrations
of the vector [46]. Furthermore, opioid-based gene therapy can be very powerful in inducing
analgesia if combined with administration of very low doses of classical opioids [46]. Besides
opioid peptides, other transgenes were included in the HSV-1 vectors constructs. A transgene
that increases the levels of the inhibitory neurotransmitter GABA, namely by overexpressing
its synthetizing enzyme glutamate decarboxylase (GAD), induced analgesia in neuropathic
pain models [26, 47]. HSV-1 based vectors have also been used to deliver transgenes that
overexpress anti-inflammatory interleukins [24, 48] or the soluble receptor for tumor necrosis
factor-α (TNF-α), which act as an antagonist of TNF-α in order to block its role as a pro-
inflammatory mediator [25, 49]. A decrease in the levels of the α subunit of the voltage-gated
sodium channel 1.7 (Nav 1.7) was also achieved using HSV-1 constructs but with the transgene
inserted in antisense orientation [16].
Other viral vectors, namely adenoviruses, adeno-associated viruses and lentiviruses have been
used to target the spinal cord, but unlike HSV-1 vectors which have been administered at the
periphery following its natural route of retrograde transport to DRG neurons, these vectors
were either directly injected into DRGs or trigeminal ganglion neurons, intrathecally or
intraspinally (Table 1). The transgenes included in adenoviruses, adeno-associated viruses are
similar to those used in HSV-1 vectors, namely opioids [17, 31], interleukins [27-29] and GAD
[42]. Adeno-associated vectors have also carried transgenes that overexpress µ-opioid
receptors [18] or block the expression of GTP cyclohydroxilase (GCH1) using small hairpin
RNAs [30]. GCH1 is the rate-limiting enzyme of an essential co-factor for nitric oxide synthase
(NOS), which modulates nociceptive transmission. Finally, lentiviral vectors have also been
used in gene transfer studies directed to the spinal cord. Based on its ability to restrict
transduction to the injection site, lentiviral vectors have been administered intraspinally in the
dorsal horn to increase the levels of a neurotrophic factor (glial-derived neurotrofic factor,
GDNF) [32] or decrease the expression of Nuclear Factor kB (NFκB), which regulates cellular
inflammation responses [33]. In the latter study, microdelivery of an HIV pseudotyped
lentiviral vector into the spinal dorsal horn led to a preferential transgene expression in glial
cells. This shows that, besides the promoter, pseudotyping the vector is a way of directing
transgene expression and glia is an important target in pain, inasmuch that chronic pain is
associated to the activation of glial cells which produce algogenic mediators that exacerbate
pain, namely NFκB. All of these approaches showed considerable analgesic efficacy and
reduced side effects.
4. Gene therapy targeting for pain: The challenge of targeting pain control
circuits in the brain
Abnormal descending pain modulation from the brain is a common feature of several chronic
pain conditions, namely those characterized by widespread pain, like fibromyalgia, which
derive from impairments in descending pain inhibition [50]. Studies with gene delivery into
the brain (Table 2) are much scarcer than spinal cord deliveries. This is due both to the higher
difficulty of surgical approaches to deliver the vectors into the brain and challenges to
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manipulate the complex brain neuronal circuits involved in pain modulation. The spinal cord
constitutes a less invasive delivery route when the aim is to manipulate descending modula‐
tory pathways (Fig. 1). This delivery route was recently explored by injecting intraspinally an
adenovirus vector targeting the expression of a potassium channel into noradrenergic
pontospinal neurons, which decreased the activity of those pontospinal neurons and induced
hyperalgesia [51]. These experiments confirm the pain inhibiting role of the noradrenergic
projections to the spinal cord [52].
Pain models Gene product Delivery References
Acute pain Proenkephalin Medullary dorsal reticularnucleus (DRt) [55]
Neuropathic Tyrosine Hydroxylaseantisense
Medullary dorsal reticular
nucleus (DRt) [34]
Inflammatory Proenkephalin Medullary ventral reticularnucleus (VLM) [19]
Inflammatory Proenkephalin Medullary dorsal reticularnucleus (DRt) [20]
Acute pain GAD Insular Cortex [38]
Inflammatory pain Preproenkephalin Amygdala [21]
Acute and Inflammatory pain NMDA antisense Medullary nucleus of thesolitary tract [56]
Inflammatory and
neuropathic pain model Potassium channel (hKir2.1)
Pontospinal noradrenergic
neurons [51]
Table 2. Summary of animal studies using viral vectors for gene transfer to pain control centers in the brain.
Gene transfer in the brain used almost exclusively HSV-1 vectors to overexpress opioid
peptides [19-21, 38] and, in a much more limited extent, GAD [38]. Our research group has a
large experience in gene transfer to pain control centres at the medulla oblongata, namely the
dorsal reticular nucleus (DRt), the caudal ventrolateral medulla (VLM) and the nucleus of the
solitary tract (NTS). These areas were elected based on the extensive neurobiological knowl‐
edge of their role in pain modulation [53, 54]. Overexpression of opioid precursors in the DRt
and VLM induced analgesia in acute pain tests and models of sustained or chronic inflamma‐
tory pain [19, 20, 55]. Brain areas involved in pain control and which are of easier neurosurgical
access are the amygdala and the rostral agranular insular cortex. Overexpression of opioid
precursors in the central amygdalar nucleus [21] or GAD in the rostral agranular insular cortex
induced analgesia in acute pain models [38]. Lentiviral vectors were delivered to the NTS, an
area which is crucial in pain and cardiovascular integration, to decrease local expression of N-
methyl-D-aspartate (NMDA) receptor, a key receptor for the action of glutamate, and this
approach was shown to decrease acute and inflammatory pain [56]. Since glutamate, is the
most ubiquitous mediator of excitatory synaptic transmission in the central nervous system
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and NMDA receptors are also expressed by glial cells, the effects of gene therapy were
restricted to NTS neurons by using the rat synapsin promoter.
There is a puzzling difference between gene therapy studies using HSV-1 vectors at the
periphery or the brain. Whereas the ability for HSV-1 to migrate retrogradely is the main
feature of studies at the periphery, the migration of HSV-1 in the brain is seldom evaluated.
This can confound the effects of gene therapy on pain responses since the effect may derive
from transduction of neurons that project to the injected area, and not at the targeted area itself.
Our research group has pioneer work in studying the dynamics of HSV-1 migration in the
brain after injections of the vector in pain control centres of the medulla oblongata, namely the
caudal medulla oblongata (VLM) and the dorsal reticular nucleus (DRt). After injections of a
HSV-1 vector expressing the lacZ reporter gene, under control of the human cytomegalovirus
promoter (hCMV), in pain control centres of the medulla oblongata, migration in VLM and
DRt afferents was detected [19, 55] (Fig. 2). However, not all the brain afferents of the VLM
and DRt exhibited β-galactosidase (β-gal), the product of lacZ expression. For example, the
amygdala and the cortex, which are important VLM and DRt afferents [57, 58] did not show
neurons expressing β-gal.
Figure 2. Dynamics of HSV-1 migration in the brain after injection into the DRt. Photomicrographs of β-gal positive
neurons in the cerebellum (A), the parabrachial complex (B), the locus coeruleus (C) and the VLM (D) at 7 days post-
injection Scale bar D: 100 μm (photomicrographs A-C are at the same magnification).
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Although it could be argued that this is due to lack of activity of the hCMV promoter in
amygdalar and cortical neurons, other studies showed that hCMV is active in those neurons
[21, 59]. These results rather point to a selective uptake of HSV-1 vectors injected in the brain
parenchyma, probably due to interactions between neuronal receptors and glycoproteins of
the HSV-1 envelope. By carefully mapping the brain areas exhibiting retrograde transport after
HSV-1 injections in the brain using immunohistochemical detection of the gene reporter and
in situ hybridization against the DNA of HSV-1, the problems of affecting brain afferents of
the injected area can be circumvented.
The selective migration of HSV-1 in the brain can be a useful feature of the vector. After
establishing the dynamics of the migration of HSV-1 in the brain after injection into the DRt
(a facilitatory pain control centre of the brain), we used a tissue specific promoter (tyrosine
hydroxylase-TH) to direct the expression of the vector to the noradrenergic afferents of the
DRt (Fig. 3). Based on the analgesic effects of the administration of α1-adrenorecetor antago‐
nists into the DRt, the TH transgene was inserted in antisense orientation into the vector in
order to decrease the levels of noradrenaline in the DRt [34]. A sustained analgesic effect was
achieved in a model of neuropathic pain, which reproduces clinically relevant features of
neuropathic pain. The fact that the analgesic effects were so long, lasting for 2 months with a
single vector injection, and reversed several pain modalities, indicates that targeting pain
control centres of the brain needs to be considered both in animal and pre-clinical studies.
5. Gene therapy for chronic pain at the bedside: Human studies
The translational perspectives of the studies summarized in section 2, namely those using
replication-defective HSV-1 vectors, favoured the approval of clinical trials for gene therapy
for chronic pain. An important reinforcement of the proof-of-concept for the potential utility
of HSV-based vector in rodent pain models was provided by equivalent studies performed in
primates [36]. These studies were important since the translational perspectives of the rodent
results were questioned for several reasons, such as the larger size of dermatomes of humans.
The first clinical trial of gene therapy for pain was a safety and dose-escalation Phase I study
in ten patients with mild to severe intractable pain due to terminal cancer [60]. The protocol
consisted in the administration directly in the pain-reporting area of an HSV-1 replication-
defective vector containing the transgene of the precursor of enkephalin [61]. A dose-depend‐
ent analgesic effect was demonstrated with a reduction of pain scores lasting for at least 2
weeks and with no adverse effects. These encouraging results prompt to implement a Phase
II trial in a larger cancer population and the study includes placebo controls, evaluation of the
effects of reinoculation of the vector and assessment of the maximal dose [45, 62].
The progress of the clinical trials for cancer pain opened avenues to test gene therapy to block
nociceptive transmission in the spinal cord in other pain conditions, such as painful diabetic
neuropathy. This pain type, which is increasing to the pandemic occurrence of diabetes, is
difficult to treat with conventional analgesics and only about one third of the patients achieve
a 50% pain reduction beyond the placebo effect [63]. A clinical trial has recently been approved
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to use an HSV-1 vector that overexpress GAD to relief painful diabetic neuropathy [45]. Other
therapeutic transgenes are being considered for future clinical trials of gene therapy, namely
the overexpression of interleukins [45]. The future of gene therapy for chronic pain in humans
will depend on the results of the clinical trials that are currently being performed but the
promising results obtained so far indicate that gene therapy will add to the armamentarium
of available pain treatments.
The application of gene therapy to block nociceptive transmission at supraspinal levels has
been proposed by several pain specialists [64]. However, most experimental studies dealing
with gene delivery at the brain were directed to pain control areas of the medulla oblongata,
which are of difficult neurosurgical approach since they are in close vicinity to areas involved
in the control of vital functions, such as cardiovascular and respiratory controls. Moving the
focus of the gene delivery studies to areas that are more easy to approach may be useful namely
in the context of widespread chronic pain, such as fibromyalgia and complex regional pain
syndrome [65]. This can only be considered after a thorough characterization of the pain control
Figure 3. HSV-1 injected at the DRt transduces noradrenergic afferents of the nucleus (A, B). Photomicrographs repre‐
senting double-labeled neurons for β-gal and TH (yellowish) in the locus coeruleus (A) and the A5 noradrenergic cell
group (B). β-gal positive neurons are shown in red and TH positive neurons are shown in green (A). Scale bar in B: 40
µm (A is at the same magnification). The insertion of TH in antisense orientation into HSV-1 (THa vector) induced anal‐
gesia in the spared nerve injury (SNI) model of neuropathic pain (C, D). THa induced a sustained attenuation of me‐
chanical hyperalgesia evaluated by the pin-prick test (C) and cold allodynia evaluated by the acetone test (D). THa and
the control vector were injected at time 0, i.e., 2 weeks after SNI induction. Data are presented as mean ± SEM (n=6 for
each group); *P<0.05, **P<0.01, ***P<0.001 THa- vs. control- vector.
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circuits in the brain namely in what concerns the functional changes induced by the chronic
pain condition in order to select the best brain areas to target to maximise the balance between
efficacy and risk.
6. Future challenges
The advances of gene therapy in other diseases of the nervous system rather than pain will
be crucial to define the future of gene therapy for chronic pain, namely by the improve‐
ments in the delivery systems. Studies which improved the efficacy of non-viral  vectors
already inspired the construction of a non-viral, non plasmid immunologically defined gene
expression  (MIDGE)  vector  that  overexpress  β-endorphin  and  induced  analgesia  after
injection into inflamed paws by increasing the concentration of β-endorphin in leukocytes
[66]. Since chronic pain requires long-term transgene expression, the duration of the activity
of promoters needs to be increased. It could be useful to design constructs that are activated
only when pain lasts for longer periods and rises over a certain threshold. This would allow
treating  chronic  pain  but  still  preserve  acute  pain  as  an  alert  signal.  An  interesting
possibility could be to control the activity of the promoter using inducible promoters, which
have been used in gene therapy studies other than pain. The activity of these promoters
can be induced exogenously, for example, by antibiotics. An ingenious idea was recently
applied by using a ligand (glycine) which normally is not expressed in DRG neurons but
can be administered to activate HSV-1 vectors to express glycine receptors in animal models
of  somatic  and visceral  pain [67].  Besides the vectors  and the promoters,  an election of
effective transgenes for chronic pain will be important to define the future of gene therapy
for chronic pain. Transgenes for opioid peptides have been overused in gene therapy studies
in  animal  models  but  long-term  treatments  with  classic  opioids  may  induce  pain,  a
phenomena known as opioid-induced hyperalgesia [68]. By achieving more sustained and
strong transgene expression, it is possible that opioid-induced hyperalgesia could also be
induced by gene therapy. New transgenes should be considered in future studies of gene
therapy for  chronic  pain.  Based on the role  of  the vanilloid receptor  TRPV-1 (Transient
Receptor Potential channel Vanilloid 1) as a pro-nociceptive cationic channel involved in
pain signalling, and the clinical relevance of desensitization of TRPV1 receptors [69], this
may be an important target molecule in the future. By decreasing the expression of protein
kinase C-epsilon (PKC), which phosphorylates TRPV1 receptors, it was possible to induce
analgesia in animal models [70]. Even more challenging is the possibility of targeting pain
control centres in the brain using gene therapy. These studies will continue for large years
to focus on animal pain models in order to determine neurobiological  effects of  chronic
pain installation in pain control centres, using gene therapy as a method to prevent those
changes. Finally, the emergent new field in pain research of genetics of pain has recently
provided data  which may explain  the  higher  susceptibility  of  some persons  to  develop
chronic pain [71].  Due to its versatility and the possibility of direct gene targeting, gene
therapy can be the perfect tool to verify if the holy grail of a personalized pain treatment
can be implemented.
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